ANTX vs EXEL
ANTX: AN2 Therapeutics leverages a proprietary boron chemistry platform to develop small-molecule drugs for neglected infectious diseases, blood cancers, and other high-unmet-need conditions. EXEL: Exelixis is a commercial-stage oncology biotechnology company with a strong focus on developing small-molecule treatments for various types of cancer.
Side-by-side fundamentals
| Metric | ANTX | EXEL | Edge |
|---|---|---|---|
| Price as of 2026-08-06 close | $6.08 | $52.20 | |
| Market cap as of 2026-08-08 | $219M | $12.9B | |
| P/E as of 2026-08-08 | n/a | 15.83 | |
| PEG as of 2026-08-08 | n/a | 1.19 | |
| Net margin as of 2026-08-08 | n/a | +35.1% | |
| Gross margin as of 2026-08-08 | n/a | +96.4% | |
| Operating margin as of 2026-08-08 | n/a | +39.4% | |
| ROE as of 2026-08-08 | -52.3% | +40.2% | EXEL higher |
| ROA as of 2026-08-08 | -47.3% | +30.5% | EXEL higher |
| Debt / equity as of 2026-08-08 | 0.00 | 0.00 | Tie |
| Revenue growth (YoY) as of 2026-08-08 | n/a | +7.9% | |
| Revenue CAGR (3y) SEC XBRL | n/a | +9.5% | |
| Beta as of 2026-08-08 | -0.99 | 0.47 | |
| 1-year return as of 2026-08-06 close | +465.6% | +38.4% | ANTX higher |
Fundamentals: market data, as of 2026-08-08. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-06.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.